• 1
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111: 14553.
  • 2
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890907.
  • 3
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 34250.
  • 4
    IARC. IARC working group on the evaluation of carcinogenic risks to humans: Human Papillomaviruses. Lyon, France: IARC, 2005.
  • 5
    Baseman JG,Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32( Suppl 1): S16S24.
  • 6
    McCredie MR,Sharples KJ,Paul C,Baranyai J,Medley G,Jones RW,Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 42534.
  • 7
    Zuna RE,Allen RA,Moore WE,Lu Y,Mattu R,Dunn ST. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 2007; 20: 16774.
  • 8
    Khan MJ,Castle PE,Lorincz AT,Wacholder S,Sherman M,Scott DR,Rush BB,Glass AG,Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 10729.
  • 9
    Clifford G,Franceschi S,Diaz M,Munoz N,Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24( Suppl 3): S26S34.
  • 10
    Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007; 23: 297313.
  • 11
    Stoler MH,Rhodes CR,Whitbeck A,Wolinsky SM,Chow LT,Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992; 23: 11728.
  • 12
    Duensing S,Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002; 62: 707582.
  • 13
    Wentzensen N,von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 31530.
  • 14
    Carreon JD,Sherman ME,Guillen D,Solomon D,Herrero R,Jeronimo J,Wacholder S,Rodriguez AC,Morales J,Hutchinson M,Burk RD,Schiffman M. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 4416.
  • 15
    Jeronimo J,Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006; 195: 34953.
  • 16
    Schiffman M,Adrianza ME. ASCUS-LSIL triage study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44: 72642.
  • 17
    Solomon D,Schiffman M,Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 2939.
  • 18
    Solomon D,Davey D,Kurman R,Moriarty A,O'Connor D,Prey M,Raab S,Sherman M,Wilbur D,Wright TJr,Young N. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287: 211419.
  • 19
    Dunn ST,Allen RA,Wang S,Walker J,Schiffman M. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J Virol Methods 2007; 143: 4554.
  • 20
    Jeronimo J,Wentzensen N,Long R,Schiffman M,Dunn ST,Allen RA,Walker JL,Gold MA,Zuna RE,Sherman ME,Wacholder S,Wang SS. An evaluation of linear array HPV genotyping using an automatic optical imaging software. J Clin Microbiol 2008; 46: 275965.
  • 21
    Wright TCJr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 20122.
  • 22
    de Hoon MJ,Imoto S,Nolan J,Miyano S. Open source clustering software. Bioinformatics 2004; 20: 14534.
  • 23
    Eisen MB,Spellman PT,Brown PO,Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 148638.
  • 24
    Stoler MH,Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 2001; 285: 15005.
  • 25
    Cox JT,Schiffman M,Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 140612.
  • 26
    Gravitt PE,Kovacic MB,Herrero R,Schiffman M,Bratti C,Hildesheim A,Morales J,Alfaro M,Sherman ME,Wacholder S,Rodriguez AC,Burk RD. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007; 121: 278793.
  • 27
    Fuchs PG,Girardi F,Pfister H. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int J Cancer 1988; 41: 415.
  • 28
    Kurman RJ,Schiffman MH,Lancaster WD,Reid R,Jenson AB,Temple GF,Lorincz AT. Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol 1988; 159: 2936.
  • 29
    Gage JC,Hanson VW,Abbey K,Dippery S,Gardner S,Kubota J,Schiffman M,Solomon D,Jeronimo J. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108: 26472.
  • 30
    Lorincz AT,Castle PE,Sherman ME,Scott DR,Glass AG,Wacholder S,Rush BB,Gravitt PE,Schussler JE,Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 2289.
  • 31
    Castle PE,Stoler MH,Solomon D,Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127: 80515.